Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Research output: Contribution to journalReviewResearchpeer-review

  3. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effects of endogenous GIP in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A short report of 50 patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuroendocrine neoplasms of the appendix: Characterization of 335 patients referred to the Copenhagen NET Center of Excellence

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To investigate the effect of Rosiglitazone in three patients treated with bilateral adrenalectomy followed by hyperpigmentation and hypersecretion of ACTH.

PATIENTS AND METHODS: One patient had increasing ACTH after previous transsphenoidal surgery for Nelson's syndrome, and two patients without pituitary adenomas had recurrence of Cushing's disease after primary and repeated transsphenoidal surgery with need for bilateral adrenalectomy. The patients developed hyperpigmentation and increasing ACTH at nadir 2-4 h after morning hydrocortisone dose. ACTH during Rosiglitazone therapy (4 mg/day for 4 weeks and then 8 mg/day) was measured at regular intervals 24 h after the latest dose of hydrocortisone.

RESULTS: In two patients there was a decrease in ACTH by 40% after 5 months. The first of these patients showed an escape with increasing ACTH to the initial value after 11 months. In the third patient no effect was observed. Tumour development or progression on magnetic resonance imaging was not observed.

CONCLUSION: Rosiglitazone might represent an adjuvant therapy in patients with ACTH hypersecretion. Larger long-term studies are needed.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume153
Issue number4
Pages (from-to)503-5
Number of pages3
ISSN0804-4643
DOIs
Publication statusPublished - Oct 2005

    Research areas

  • Adrenalectomy/adverse effects, Adrenocorticotropic Hormone/blood, Adult, Aged, Female, Humans, Male, Nelson Syndrome/blood, Rosiglitazone, Thiazolidinediones/therapeutic use, Time Factors, Treatment Outcome

ID: 59352983